Hope for leptomeningeal disease (LMD)

submitted by: mdanderson
Leptomeningeal disease (LMD), which is also referred to as leptomeningeal carcinomatosis (LC), is a rare complication of cancer where the disease spreads to the membranes (meninges) surrounding the brain and spinal cord. Having a diagnosis of LMD may feel grim, but Cynthia Weisinger, a LMD and stage four breast cancer patient at MD Anderson Cancer Center, represents hope. Cynthia was diagnosed with LMD by Ivo Tremont, M.D., assistant professor of Neuro-Oncology, in October 2013 and is now...

An in-mouth wafer to treat oral cancer– Biotech’s future

submitted by: nsf

To treat oral cancer, NSF-funded small business Privo Technologies has created a platform that delivers treatments directly to the affected area. Privo develops new classes of targeted treatments, such as chemotherapy drugs, designed to be delivered through the mouth’s mucous membranes. Privo founder Manijeh Goldberg talked about her company’s research at the 2014 BIO International Convention.

Top five ways to reduce cancer risk

submitted by: mdanderson

You can reduce your cancer risk by following these simple guidelines from Ernest Hawk, M.D., vice president of Cancer Prevention and Population Sciences at MD Anderson Cancer Center. Many diseases can be avoided by changing your lifestyle. Learn what you can reduce your risk for cancer.

Cancer-scanning device detects residual cancer cells post-surgery – Biotech’s future

submitted by: nsf

Despite a surgeon’s best efforts, residual cancer cells often remain after a tumor is removed. Now, a technology from NSF-funded small business NovaScan detects cancer cells in living tissue in real-time. The cancer-scanning device has already been used to find breast cancer cells. NovaScan’s William Gregory talked about how the wand works at the 2014 BIO International Convention.

Leveraging the immune system to fight cancer – Biotech’s future

submitted by: nsf

Inventors are using small-scale biology and engineering to find ways to use the body’s natural defenses to effectively treat cancer. NSF-funded small business GigaGen uses microfluidics, bioinformatics and genome sequencing to look for antibodies that may be good candidates for new therapies. GigaGen’s David Johnson explained how at the 2014 BIO International Convention.

United to End Cancer

submitted by: mdanderson

There are those who stand together to make a difference in the fight against cancer — The University of Texas MD Anderson Cancer Center’s community of donors. From across the world and all walks of life, these diverse supporters are united in their generosity toward the Moon Shots Program, the most ambitious assault on cancer ever undertaken by a single institution.

For more information and to make a donation, visit: mdanderson.org/gifts